Alvotech, Advanz Pharma Collaborate To Launch Cimzia® Biosimilar AVT10 In Europe

Alvotech and Advanz Pharma have expanded their partnership by entering a new supply and commercialization agreement for AVT10, a biosimilar candidate to Cimzia® (certolizumab pegol). The reference product, Cimzia®, generated global sales of $2.3 billion in 2024.

“Our biosimilar candidate is the only one referencing Cimzia® that is under development globally and the reference product has carved out significant market share as treatment for chronic rheumatic diseases, especially for women of childbearing age. I’m very pleased to add it to our expanding commercial partnership with Advanz Pharma,” said Róbert Wessman, Chairman and CEO of Alvotech.

This agreement builds on an already extensive collaboration between the two companies, which previously partnered on biosimilar candidates referencing more than ten biologic medicines. The strategic focus remains on bringing affordable, high-quality biosimilars to the European market, targeting hospital and specialty care settings.

“This agreement further strengthens our strategic partnership with Alvotech and supports our goal to expand access to high-quality biologics for patients in Europe. A proposed biosimilar to Cimzia® is a valuable addition to our sizable biosimilars pipeline,” said Steffen Wagner, CEO of Advanz Pharma.

The companies anticipate that AVT10 and other biosimilars from their pipeline will begin launching in Europe as early as Q4 2025, supporting greater patient access and health system sustainability across the region.